| Not Yet Recruiting | Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AML Acute Myeloid Leukemia, TP53 Gene Mutation | Phase 1 | 2026-08-01 |
| Recruiting | Early Use of Tacrolimus in HLA-Mismatched Haploidentical Allogeneic Hematopoietic Transplantation With Post-Tr Hematologic Disease and Disorders, Hematopoietic Cell Transplant | Phase 2 | 2025-07-03 |
| Recruiting | CAR T-cell Therapy in Patients With Renal Dysfunction Non-hodgkin Lymphoma,B Cell, Multiple Myeloma, Acute Lymphoblastic Leukemia, Adult | Phase 2 | 2024-11-18 |
| Withdrawn | Adding Venetoclax to the High-dose Chemotherapy Regimen Prior to Mismatche Allogeneic Stem Cell Transplant Acute Myeloid Leukemia, Myelodysplastic Syndromes | Phase 2 | 2024-08-31 |
| Recruiting | Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Disease Chronic Graft Versus Host Disease | Phase 2 | 2024-01-29 |
| Recruiting | Intrathecal Chemoprophylaxis to Prevent Neurotoxicity Associated With Blinatumomab Therapy for Acute Lymphobla Acute Lymphoblastic Leukemia | Phase 2 | 2023-06-30 |
| Recruiting | Reduced Intensity Fludarabine and TBI Prior to Haplo-Identical Transplantation Hematologic Malignancy | — | 2022-08-29 |
| Terminated | Use of Convalescent Plasma for COVID-19 COVID | Phase 2 | 2020-07-14 |
| Recruiting | GM-CSF With Post-Transplant Cyclophosphamide Transplant-Related Hematologic Malignancy | Phase 2 | 2020-05-18 |
| Terminated | Ibrutinib and Rituxan for Chronic GVHD Graft Vs Host Disease | Phase 2 | 2019-12-16 |
| Completed | Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in AML Patient Not Eligible for Transplant Acute Myeloid Leukemia | Phase 2 | 2016-09-28 |
| Recruiting | Haploidentical Bone Marrow Transplant With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Severe Aplastic Anemia | Phase 2 | 2016-09-09 |
| Completed | Reduced Intensity Conditioning Transplant Using Haploidentical Donors Chronic Myelogenous Leukemia, Acute Myelogenous Leukemia, Myelodysplastic Syndrome | Phase 2 | 2015-10-26 |
| Completed | High Dose Chemotherapy Using BeEAM for Autologous Transplant in Multiple Myeloma Multiple Myeloma | Phase 2 | 2015-04-27 |
| Completed | Nonmyeloablative Haploidentical Transplant Followed by MLN9708 Acute Leukemia, Chronic Leukemia, Myelodysplastic Syndrome | Phase 2 | 2014-07-15 |
| Terminated | MOSTEGRA TRIAL:MO-(Dified) STE-(nt) GRA(-ft): Surgeon-modified Fenestrated-branched Stent-grafts Complex Aortic Aneurysms | N/A | 2012-08-28 |
| Completed | Palonosetron, Ondansetron, and Dexamethasone for Delayed Nausea and Vomiting in Autologous Transplant Patients Chemotherapy-induced Nausea and Vomiting | Phase 2 | 2012-02-01 |
| Completed | Rituximab for the Primary Treatment of Denovo Extensive Chronic Graft Versus Host Disease (GVHD) Chronic Graft-versus-host Disease | Phase 2 | 2011-04-01 |
| Completed | Total Body Irradiation/Fludarabine Based Ablative Haploidentical Transplant for Hematologic Diseases Chronic Leukemia, Acute Leukemia, Hodgkin's Disease | Phase 2 | 2011-04-01 |
| Completed | FOB in HSCT and Leukemia Patients With Acute Respiratory Symptoms and Pulmonary Infiltrates Pulmonary Infiltrate New | N/A | 2011-03-01 |
| Completed | Post-transplant Cyclophosphamide and Sirolimus Following Reduced Intensity Conditioning (RIC) Transplant Hematologic Neoplasms | Phase 2 | 2010-12-01 |
| Completed | Caregiver Burden and Distress in Hematopoeitic Stem Cell Transplant Depression, Anxiety, Fatigue | — | 2010-04-19 |
| Completed | Combination Chemotherapy, Donor Stem Cell Transplant, Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide Leukemia, Lymphoma, Myelodysplastic Syndromes | Phase 2 | 2008-10-01 |
| Completed | Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Tr Myeloproliferative Disorders, Kidney Cancer, Leukemia | Phase 2 | 2007-04-01 |
| Terminated | Umbilical Cord Blood (UCB) Transplant, Fludarabine, Melphalan, and Anti-thymocyte Globulin (ATG) in Treating P Myeloproliferative Disorders, Leukemia, Lymphoma | Phase 2 | 2006-06-01 |
| Terminated | Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer Leukemia, Lymphoma, Myelodysplastic Syndromes | Phase 2 | 2005-05-01 |